AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) and Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Risk & Volatility
AirSculpt Technologies has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, Guardian Pharmacy Services has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.
Valuation and Earnings
This table compares AirSculpt Technologies and Guardian Pharmacy Services”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AirSculpt Technologies | $151.82 million | 0.77 | -$11.67 million | ($0.18) | -9.00 |
| Guardian Pharmacy Services | $1.45 billion | 1.37 | $49.22 million | $1.03 | 38.69 |
Guardian Pharmacy Services has higher revenue and earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AirSculpt Technologies and Guardian Pharmacy Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AirSculpt Technologies | -7.79% | -5.83% | -2.88% |
| Guardian Pharmacy Services | 4.50% | 29.97% | 16.18% |
Institutional & Insider Ownership
91.5% of AirSculpt Technologies shares are owned by institutional investors. 44.6% of AirSculpt Technologies shares are owned by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings for AirSculpt Technologies and Guardian Pharmacy Services, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AirSculpt Technologies | 1 | 1 | 0 | 0 | 1.50 |
| Guardian Pharmacy Services | 0 | 1 | 9 | 0 | 2.90 |
AirSculpt Technologies presently has a consensus target price of $4.50, suggesting a potential upside of 177.78%. Guardian Pharmacy Services has a consensus target price of $45.57, suggesting a potential upside of 14.34%. Given AirSculpt Technologies’ higher probable upside, research analysts plainly believe AirSculpt Technologies is more favorable than Guardian Pharmacy Services.
Summary
Guardian Pharmacy Services beats AirSculpt Technologies on 9 of the 13 factors compared between the two stocks.
About AirSculpt Technologies
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas. The company’s body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Receive News & Ratings for AirSculpt Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AirSculpt Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
